American Journal of Clinical Dermatology最新文献_第4页

Is There a Place for Biologics in Acne? 生物制剂在痤疮中有一席之地吗？

IF 8.8 1区医学

American Journal of Clinical Dermatology Pub Date : 2025-06-05 DOI: 10.1007/s40257-025-00954-8

Lajos Kemény, Döníz Degovics, Kornélia Szabó

{"title":"Is There a Place for Biologics in Acne?","authors":"Lajos Kemény, Döníz Degovics, Kornélia Szabó","doi":"10.1007/s40257-025-00954-8","DOIUrl":"10.1007/s40257-025-00954-8","url":null,"abstract":"<div><p>Acne vulgaris is a chronic inflammatory skin condition with a multifactorial pathogenesis involving follicular hyperkeratinization, sebaceous gland dysregulation, microbial dysbiosis—particularly involving <i>Cutibacterium acnes</i> and <i>Staphylococcus epidermidis</i>—and complex immune-mediated mechanisms, on which T helper cell 1 (T<sub>h</sub>1) and T<sub>h</sub>17 pathways are central players. This evolving understanding has led to the exploration of biologic therapies targeting cytokines such as tumor necrosis factor-alpha (TNFα), interleukin (IL)-1, IL-17, and IL-23. However, clinical trials to date have not demonstrated efficacy of biologics in moderate to severe acne. In contrast, some case reports and studies suggest clinical improvement with TNFα and IL-17A inhibitors in severe, treatment-resistant acne, although these presentations often overlap with hidradenitis suppurativa (HS), raising questions about diagnosis and underlying disease mechanisms. Furthermore, in various monogenic autoinflammatory syndromes where “acne-like” lesions are part of the clinical spectrum, biologic therapies have shown effectiveness. These observations suggest that in such contexts, the lesions may reflect HS or HS-like pathology rather than true acne, potentially explaining the therapeutic benefit of biologicals in this context. This review synthesizes current insights into the immunopathogenesis of acne and critically evaluates the rationale, evidence, and limitations of biologic therapy in its treatment. While biologics hold promise in defined inflammatory dermatoses, their role in the management of acne vulgaris remains unproven and may be limited to specific phenotypes that overlap with autoinflammatory or HS-related conditions.</p></div>","PeriodicalId":7706,"journal":{"name":"American Journal of Clinical Dermatology","volume":"26 5","pages":"667 - 676"},"PeriodicalIF":8.8,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40257-025-00954-8.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144232993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction to: Long-Term Safety and Tolerability of Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Extension Study of Patients with Dystrophic Epidermolysis Bullosa 修正：在营养不良大疱性表皮松解症患者的开放标签扩展研究中，Beremagene Geperpavec-svdt （B-VEC）的长期安全性和耐受性。

IF 8.8 1区医学

American Journal of Clinical Dermatology Pub Date : 2025-06-04 DOI: 10.1007/s40257-025-00956-6

M. Peter Marinkovich, Amy S. Paller, Shireen V. Guide, Mercedes E. Gonzalez, Anne W. Lucky, Işın Sinem Bağcı, Brittani Agostini, Kolleen Fitzgerald, Shijie Chen, Hubert Chen, Meghan M. Conner, Suma M. Krishnan

引用次数: 0

Cutaneous T Cell Lymphoma Following Dupilumab Therapy in Patients with Atopic Dermatitis: Clinical Review and Recommendations 特应性皮炎患者接受杜比单抗治疗后的皮肤T细胞淋巴瘤：临床回顾和建议。

IF 8.8 1区医学

American Journal of Clinical Dermatology Pub Date : 2025-05-26 DOI: 10.1007/s40257-025-00955-7

Leore Lavin, Shamir Geller

{"title":"Cutaneous T Cell Lymphoma Following Dupilumab Therapy in Patients with Atopic Dermatitis: Clinical Review and Recommendations","authors":"Leore Lavin, Shamir Geller","doi":"10.1007/s40257-025-00955-7","DOIUrl":"10.1007/s40257-025-00955-7","url":null,"abstract":"<div><p>The complex interplay between atopic dermatitis (AD) and cutaneous T cell lymphomas (CTCL) has been known as a matter of clinical concern. With the widespread use of dupilumab, a monoclonal antibody inhibiting interleukin-4 receptor alpha (IL-4Ra) and interleukin-13 receptor (IL-13R), potential association between dupilumab and developing CTCL has been reported in patients with AD. Disease progression has also been described in patients with known CTCL who were treated with dupilumab. Although population-based and pharmacovigilance data support an increased risk of CTCL with dupilumab use in patients with AD, it is a rare association, most likely occurring in predisposed patients. No evidence is available to support a direct oncogenic risk of transforming AD into lymphoma by the treatment, and current literature suggests the role of IL-4Ra/IL-13R inhibition in unmasking pre-existing malignant T cell clones through increased IL-13 availability. On the basis of a comprehensive literature review and our experience in a cutaneous lymphoma clinic at a tertiary cancer center, we provide practical clinical care recommendations for the use of dupilumab in patients with AD, CTCL, and non-skin lymphomas. We also highlight the need for further researching alternative diagnostic approaches to differentiate CTCL from AD and other inflammatory skin disorders and studying the roles of IL-13 and its receptors in CTCL and the effect of the newly available IL-13-inhibiting therapies.</p></div>","PeriodicalId":7706,"journal":{"name":"American Journal of Clinical Dermatology","volume":"26 5","pages":"723 - 731"},"PeriodicalIF":8.8,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144141136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-World Effectiveness, Safety, and Drug Survival of Risankizumab in Adult Patients with Plaque Psoriasis: A 3-Year Multicenter Retrospective Cohort Study 成人斑块型银屑病患者中Risankizumab的实际有效性、安全性和药物生存期：一项为期3年的多中心回顾性队列研究

IF 8.8 1区医学

American Journal of Clinical Dermatology Pub Date : 2025-05-24 DOI: 10.1007/s40257-025-00951-x

Tiago Torres, Ana Luísa João, Martim Luz, Pedro Mendes-Bastos, Ângela Roda, Luiz Leite, Joana Valério, Ana Ferreirinha, Barbara Leal, Maria João Paiva Lopes, Rita Pimenta, Paulo Ferreira

引用次数: 0

Mastocytosis in the Skin: Approach to Diagnosis, Evaluation, and Management in Adult and Pediatric Patients 皮肤肥大细胞增多症：成人和儿童患者的诊断、评估和管理方法。

IF 8.8 1区医学

American Journal of Clinical Dermatology Pub Date : 2025-05-20 DOI: 10.1007/s40257-025-00947-7

Lauren M. Madigan, Nathan A. Boggs, Anton V. Rets, Alejandro A. Gru, Tsewang Tashi, David A. Wada, Scott R. Florell, Melody C. Carter

{"title":"Mastocytosis in the Skin: Approach to Diagnosis, Evaluation, and Management in Adult and Pediatric Patients","authors":"Lauren M. Madigan, Nathan A. Boggs, Anton V. Rets, Alejandro A. Gru, Tsewang Tashi, David A. Wada, Scott R. Florell, Melody C. Carter","doi":"10.1007/s40257-025-00947-7","DOIUrl":"10.1007/s40257-025-00947-7","url":null,"abstract":"<div><p>Mastocytosis is characterized by the clonal infiltration and proliferation of neoplastic mast cells into target organs. Clinical features of mastocytosis are based in large part on dysregulated mast cell mediator release. Affected individuals may present with isolated skin involvement or multisystemic disease with a spectrum of symptoms including anaphylaxis, pathologic fractures, and chronic gastrointestinal, neurocognitive, musculoskeletal, and constitutional symptoms. The term “mastocytosis in the skin” refers to individuals with cutaneous infiltration and encompasses both localized and systemic forms of disease. Cutaneous involvement is further categorized into cutaneous mastocytoma, diffuse cutaneous mastocytosis, and maculopapular cutaneous mastocytosis based on morphology. In ~95% of patients with systemic mastocytosis, the disease is driven by the <i>KIT</i> D816V somatic variant. The aim of this clinical review is to highlight the diagnostic considerations, management complexities, and evolving treatment landscape that must be considered when evaluating a patient presenting with mastocytosis in their skin. Clinical manifestations, histopathology, and laboratory parameters are essential to diagnosis and determining the disease burden in those with known or suspected systemic mastocytosis. Once appropriately staged, both skin-directed therapy as well as novel systemic treatment options, including selective tyrosine kinase inhibitors, can be considered with the potential to improve patient outcomes.</p></div>","PeriodicalId":7706,"journal":{"name":"American Journal of Clinical Dermatology","volume":"26 4","pages":"499 - 510"},"PeriodicalIF":8.8,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12325572/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144109403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pigmented Lesions of the Oral Mucosa: Clinical Presentation, Histology, and Recommendations for Management 口腔黏膜色素病变：临床表现、组织学和治疗建议。

IF 8.8 1区医学

American Journal of Clinical Dermatology Pub Date : 2025-05-14 DOI: 10.1007/s40257-025-00950-y

Rachelle Wolk, Daniela Massi, Denise Trochesset

{"title":"Pigmented Lesions of the Oral Mucosa: Clinical Presentation, Histology, and Recommendations for Management","authors":"Rachelle Wolk, Daniela Massi, Denise Trochesset","doi":"10.1007/s40257-025-00950-y","DOIUrl":"10.1007/s40257-025-00950-y","url":null,"abstract":"<div><p>Pigmented lesions of the oral cavity can present significant diagnostic challenges because of their diverse etiologies and similar clinical presentations. Understanding these lesions is crucial for correct diagnosis and management because the biologic behavior ranges from benign physiologic variations to aggressive malignancies. The spectrum of oral lesions can include melanin-associated and exogenous pigmented lesions such as physiologic pigmentation and an amalgam tattoo, reactive processes such as smoker’s melanosis and post-inflammatory pigmentation, benign neoplasms such as melanocytic nevi, and malignant conditions such as oral mucosal melanoma. Unlike cutaneous malignant melanomas, mucosal melanomas show distinct molecular profiles, with a lower prevalence of <i>BRAF</i><sup><i>V600E</i></sup> mutations and a higher prevalence of <i>c-KIT</i> (CD117) mutations, which impacts therapeutic approaches. While most oral pigmented lesions are benign, they require a careful clinical evaluation, and when indicated, a biopsy for definitive diagnosis. This comprehensive review enables clinicians to navigate the complicated spectrum of oral pigmented lesions for optimal patient care. </p></div>","PeriodicalId":7706,"journal":{"name":"American Journal of Clinical Dermatology","volume":"26 5","pages":"761 - 775"},"PeriodicalIF":8.8,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144075523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction to: Disease Burden and Treatment Patterns Among US Patients with Hidradenitis Suppurativa: A Retrospective Cohort Study 更正：美国化脓性汗腺炎患者的疾病负担和治疗模式：一项回顾性队列研究。

IF 8.8 1区医学

American Journal of Clinical Dermatology Pub Date : 2025-05-14 DOI: 10.1007/s40257-025-00938-8

Amit Garg, Yvonne Geissbühler, Emma Houchen, Nilesh Choudhary, Disha Arora, Varun Vellanki, Abhishek Srivastava, Priyanka, John Darcy II, Craig Richardson, Alexa B. Kimball

引用次数: 0

Disease Modification in Psoriasis: Future Prospects for Long-Term Remission 牛皮癣的疾病改变：长期缓解的未来前景。

IF 8.8 1区医学

American Journal of Clinical Dermatology Pub Date : 2025-05-06 DOI: 10.1007/s40257-025-00949-5

David Ranzinger, Kilian Eyerich

{"title":"Disease Modification in Psoriasis: Future Prospects for Long-Term Remission","authors":"David Ranzinger, Kilian Eyerich","doi":"10.1007/s40257-025-00949-5","DOIUrl":"10.1007/s40257-025-00949-5","url":null,"abstract":"<div><p>A subset of patients with moderate-to-severe psoriasis show long-term remission after drug withdrawal lasting well beyond several half-life times of the drug, particularly following effective treatment with modern biologics such as interleukin-23 inhibitors. Furthermore, evidence suggests that the development of comorbidities, including psoriatic arthritis, a key comorbidity causing irreversible damage, can be prevented or delayed in a subgroup of patients with psoriasis receiving these therapies. This implies that psoriasis treatments may alter the underlying disease mechanisms in some individuals, extending beyond their direct pharmacological effects. However, this concept of disease modification remains controversial, as predicting the natural clinical course of an individual patient with psoriasis is challenging, and typically, no permanent clinically detectable changes occur in psoriatic skin inflammation. This article aims to provide an overview of the current evidence on disease modification in psoriasis and discusses clinical and molecular markers that could be used to predict or monitor disease modification in psoriasis.</p></div>","PeriodicalId":7706,"journal":{"name":"American Journal of Clinical Dermatology","volume":"26 4","pages":"477 - 486"},"PeriodicalIF":8.8,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12227372/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143962140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction to: Real-World Evidence of Tralokinumab Effectiveness and Safety: A Systematic Review and Meta-analysis 修正：曲洛单抗有效性和安全性的真实世界证据：一项系统评价和荟萃分析。

IF 8.8 1区医学

American Journal of Clinical Dermatology Pub Date : 2025-04-24 DOI: 10.1007/s40257-025-00948-6

Amalie Thorsti Møller Rønnstad, Christopher G. Bunick, Raj Chovatiya, Masahiro Kamata, Mia-Louise Nielsen, Daniel Isufi, Simon F. Thomsen, Christian Vestergaard, Andreas Wollenberg, Alexander Egeberg, Jacob P. Thyssen, Nikolai Loft

引用次数: 0

JAK Inhibitors and Inflammatory Nail Disorders: A Systematic Review of Clinical Outcomes and Therapeutic Potential JAK抑制剂和炎症性指甲疾病：临床结果和治疗潜力的系统综述。

IF 8.8 1区医学

American Journal of Clinical Dermatology Pub Date : 2025-04-23 DOI: 10.1007/s40257-025-00946-8

Matilde Iorizzo, Andrea Sechi, Zachary J. K. Neubauer, Maggie Zhou, Shari R. Lipner

{"title":"JAK Inhibitors and Inflammatory Nail Disorders: A Systematic Review of Clinical Outcomes and Therapeutic Potential","authors":"Matilde Iorizzo, Andrea Sechi, Zachary J. K. Neubauer, Maggie Zhou, Shari R. Lipner","doi":"10.1007/s40257-025-00946-8","DOIUrl":"10.1007/s40257-025-00946-8","url":null,"abstract":"<div><h3>Background</h3><p>Inflammatory nail disorders can have a significant impact on patients’ quality of life owing to aesthetic and functional concerns. They are also challenging to treat because the therapeutic armamentarium is quite limited. This systematic review aims to report the efficacy and safety of Janus kinase and Tyrosine kinase 2 inhibitors in treating these conditions.</p><h3>Methods</h3><p>We conducted a comprehensive search on PubMed, Cochrane, and Embase Library to find eligible case reports, case series, single-arm clinical trials, and randomized controlled trials. We used the following search terms from inception until 15 December, 2024: “nail” AND “jak inhibitors” OR “tofacitinib” OR “baricitinib” OR “abrocitinib” OR “ruxolitinib” OR “deuruxolitinib” OR “upadacitinib” OR “ritlecitinib” OR “deucravacitinib” (nine searches in total).</p><h3>Results</h3><p>Of 441 articles found, 31 were included in this study. The most extensively studied drug was tofacitinib, followed by baricitinib, deucravacitinib, upadacitinib, and abrocitinib. Janus kinase/Tyrosine kinase 2 inhibitors demonstrated improvements in inflammatory nail conditions, with generally mild adverse events (nasopharyngitis and transient laboratory abnormalities being most common). The topical formulation of tofacitinib, the only one studied in these nail diseases, also demonstrated promising results with minimal systemic absorption and no side effects.</p><h3>Conclusions</h3><p>This review highlights Janus kinase/Tyrosine kinase 2 inhibitors as a valuable addition to the therapeutic arsenal for inflammatory nail disorders while emphasizing the importance of safety assessments and tailored treatment approaches. The long-term safety of Janus kinase/Tyrosine kinase 2 inhibitors still needs further investigation and the potential for adverse events emphasizes the need for tailored therapeutic strategies, including more studies on topical formulations.</p></div>","PeriodicalId":7706,"journal":{"name":"American Journal of Clinical Dermatology","volume":"26 4","pages":"525 - 536"},"PeriodicalIF":8.8,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143958551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0